All Resources

Private Drug Coverage • November 25, 2022

Cost Drivers: Analysis of Private Drug Plans in Canada 2022

Learn more|View

Access to Medicine • November 17, 2022

Innovative Agreements Framework

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Honourable Jean-Yves Duclos, P.C., M.P.

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Hon. Chrystia Freeland, P.C., M.P.

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Honourable Mary Ng, P.C., M.P.

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Ministerial PMPRB Guideline Letter to The Hon. François-Philippe Champagne, P.C., M.P.

Learn more|View

Economic Impact • October 07, 2022

Pre-Budget Consultations in Advance of the 2023 Budget

Learn more|View

Access to Medicine • July 06, 2022

Developing a Pan-Canadian Genomics Strategy: Innovative Medicines Canada Response

Learn more|View

Access to Medicine • June 28, 2022

Search for Specific Brand Name Drug Negotiations Status with the pCPA

Use this tool to search for brand name drugs to view their current negotiation status….

Learn more|View

Access to Medicine • February 05, 2022

Bluesky Project

Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…

Learn more|View

January 14, 2022

2022 Ontario Pre-Budget Consultation

Learn more|View

Ethics • January 01, 2022

2022 Code of Ethical Practices

Our Code of Ethical Practices guides the activities of all our members’ employees as they interact with stakeholders to commercialize prescription medicines (excluding medical devices and over-the-counter products). Adherence to…

Learn more|View